About the Symposium
The symposium is for students, trainees, active researchers, clinicians and those who may not presently be engaged directly in HIV research. It will feature leading scientists and clinicians describing the current state of the art in HIV/AIDS research and clinical care, highlighting recent progress in key areas, remaining major challenges, and approaches to overcome those challenges.
The meeting is intended to place emphasis on aspects of HIV research with the potential to impact clinical care and vaccine design. The scope of the meeting will extend to KSHV, as well.
Agenda
*Agenda subject to change
Reception, 5:30-7 p.m.
Whitaker Campus Commons
Welcome & Introductions, 7 p.m.
Hodson Auditorium, Rosenstock Hall
- Andrea E. Chapdelaine, Ph.D.
President, Hood College - Ethan Dmitrovsky, M.D.
Director, Frederick National Laboratory for Cancer Research
Keynote, 7:30 p.m.
Salim S. Abdool Karim, Ph.D.
Director, Centre for AIDS Program of Research, South Africa (CAPRISA)
CAPRISA Professor of Global Health, Columbia University
Special Advisor to the Director-General of the World Health Organization
Pro Vice-Chancellor (Research), University of KwaZulu-Natal
Adjunct Professor of Medicine, Weill Medical College of Cornell University
Session 1: Epidemiology of HIV Disease
- 7:30-8 a.m., Networking
Continental breakfast will be provided. - 8-8:15 a.m., Introduction
Douglas Lowy, Principal Deputy Director, National Cancer Institute - 8:15-9 a.m., HIV: History, Current Status, Future Challenges and Strategies
Speaker TBD
Session 2: Vaccine Prevention
- 9:05-9:30 a.m., Modeling and Computational Approaches to Next Generation Vaccine Design for T-Cell and Antibody Responses
Arup K. Chakraborty, John M. Deutch Institute, Professor Chemical Engineering, Physics and Chemistry
Massachusetts Institute of Technology - 9:35-10 a.m., T-Cell Vaccines Targeting Conserved, Constrained Epitopes
Gaurav D. Gaiha, Principal Investigator and Group Leader, Ragon Institute of MGH, MIT and Harvard - 10:05-10:15 a.m., Break
- 10:15-10:40 a.m., Efficacy and Mechanisms of Unconventionally Restricted CMV-Vectored T-Cell Vaccines
Louis J. Picker, Professor, VGTI-Vaccine and Gene Therapy Institute, Molecular Microbiology and Immunology Graduate Program, School of Medicine, Program in Molecular and Cellular Biosciences, School of Medicine, Oregon Health & Science University - 10:45-11:10 a.m., HIV Vaccine Immunogen Design for Induction of Broadly Neutralizing Antibodies
William Schief, Professor, Department of Immunology and Microbiology, Scripps Research Institute - 11:15-11:40 a.m., Application of Systems Immunology to Improve Vaccines
Bali Pulendran, Violetta L. Horton Professor, Stanford University School of Medicine - 11:45 a.m.-12:10 p.m., Improving Efficacy with Alternative Vaccine Delivery Approaches
Darrell Irvine, Underwood-Prescott Professor, Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology - 12:15-1:30 p.m., Lunch
Session 3: Non-Vaccine Prevention: bNAbs and Long-Acting Anti-Retrovirals
- 1:30-1:55 p.m., Passive Prophylaxis with bNAbs
Dennis Burton, Professor, Immunology and Microbiology, Scripps Research Institute, Director, AIDS Vaccine Research IAVI Neutralizing Antibody Center - 2-2:25 p.m., AAV Vectored Delivery of Antibodies
Ronald Desrosiers, Professor, Pathology, University of Miami Miller School of Medicine - 2:30-2:55 p.m., Cabotegravir for PrEP
Raphael J. Landovitz, Professor of Medicine, Interim Chief, Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, Director, UCLA Center for Clinical AIDS Research & Education, Co-Director Center for HIV Identification, Prevention, and Treatment Services - 2:55-3:10 p.m., Break
- 3:10-3:35 p.m., Preclinical NHP Studies of Lenacapavir for PrEP
Gregory Del Prete, Principal Investigator, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research - 3:40-4:05 p.m., Clinical Testing of Lenacapavir for PrEP
Laurie VanderVeen, Director, Gilead Sciences
Session 4: Treatment of HIV Infection: State of the ART
- 7:30-8 a.m., Networking
Continental breakfast will be provided - 8:05-8:25 a.m., PEPFAR at 20
Nelson L. Michael, Director, Center for Infectious Disease Research, Walter Reed Army Institute of Research - 8:30-8:55 a.m., Experience with Roll Out of Modern ART in an Upper Middle-Income Country
Gustavo Reyes Terán, Head of the Coordinating Commission, National Health Institutes and High Specialty Hospitals, Mexico - 9-9:25 a.m., Current Status and Challenges in Treatment of HIV Infection
Steven Deeks, Professor of Medicine, University of California San Francisco, Faculty Member, Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital - 9:30-9:55 a.m., Chronic Inflammation and Other Co-Morbidities in Treated HIV Infection
Peter W. Hunt, Professor of Medicine, University of California San Francisco Associate Chief for Research, ZSFG-UCSF Department of Medicine, Department of Medicine, Division of Experimental Medicine - 9:55-10:10 a.m., Break
Session 5: CNS Infection in HIV; KSHV
- 10:10-10:35 a.m., CNS Infection with HIV
Sarah Joseph, Assistant Professor, University of North Carolina School of Medicine, Microbiology and Immunology - 10:40-11:05 a.m., KSHV Virology and Epidemiology
Angela Nalwoga, Assistant Research Professor, Immunology and Microbiology, University of Colorado School of Medicine, Anschutz Medical Campus - 11:10-11:35 a.m., Clinical Aspects and Treatment KSHV Associated Disease
Robert Yarchoan, Chief, HIV and AIDS Malignancy Branch, Center for Cancer Research, Director, Office of HIV and AIDS Malignancy, National Cancer Institute - 11:40 a.m.-12:05 p.m., KSHV PDX Models to Guide Treatment
Laurie T. Krug, Stadtman Investigator, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute - 12:05-1:30 p.m., Lunch
Session 6: HIV Rebound Competent Viral Reservoir and Towards a Cure
- 1:30-1:55 p.m., Molecular Aspects of the HIV Reservoir
Xu Yu, Associate Professor of Medicine, Harvard Medical School, Physician Investigator, Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Associate Immunologist, Brigham and Woman's Hospital - 2-2:25 p.m., Strategies for HIV Cure
Sharon Lewin, Director, The Peter Doherty Institute for Infection and Immunity, Professor of Medicine, The University of Melbourne - 2:30-2:55 p.m., Gene Therapy for HIV Infection
Hans-Peter Kiem, Deputy Director, Translational Science and therapeutics Division, Professor, Vaccine and Infectious Disease Division - 3-3:15 p.m., Break
- 3:15-4:15 p.m., Panel Discussion: Moderator - Jon Cohen, Science Magazine
- Mike McCune, Head, HIV Frontiers, Bill & Melinda Gates Foundation
- Mike Saag, Professor of Medicine-Infectious Diseases, University of Alabama at Birmingham
- Daria Hazuda, Head of Infectious Diseases and Vaccine Research, Generate Biomedicines (former VP of Infectious Diseases and Vaccines and Chief Scientific Officer, Merck Cambridge Research)
- Lynda Dee, Community Engagement Coordinator DARE MDC AIDS Action Baltimore, Executive Director
- John Coffin, Tufts University School of Medicine
- 4:15 p.m., Closing Remarks (meeting summary, vision for the future of HIV)
- Jeff Lifson, Director, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research
- Mary Carrington, Director, Basic Science Program, Frederick National Laboratory for Cancer Research
Are you ready to say Hello?
Choose a Pathway
Information will vary based on program level. Select a path to find the information you're looking for!